Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

Investigator: Constance Mobley, MD

Study Coordinator: Susan Dorman

Status: Active

ClinicalTrials.gov Number: NCT02612428

Phone: 713.441.6316

Protocol Number: Pro00014326


The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) through at least Study Day 91. The secondary objective is to evaluate the proportion of survivors at Study Day 91 using a chi-squared test.
More to Explore